Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 10/19 07:32:00 am
60.686 EUR   +0.08%
10/17UCB SA : quaterly earnings release
10/17 UCB : Transparency notification The Capital Group Companies
10/13 UCB : Transparency notification The Capital Group Companies
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo UCB
Engages in the research, development, and commercialization of pharmaceutical and biotechnology products

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.

It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.

The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Number of employees : 7 563 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Cimzia®1,08327.9%1,30731.3% +20.68%
Keppra® (including Keppra® XR)737.0019%724.0017.3% -1.76%
Vimpat®679.0017.5%814.0019.5% +19.88%
Other Products431.0011.1%329.007.9% -23.67%
Neupro®258.006.7%302.007.2% +17.05%
Zyrtec® (including Zyrtec-D®/Cirrus®)147.003.8%140.003.4% -4.76%
Xyzal®117.003%107.002.6% -8.55%
Venlaflaxine XR90.002.3%90.002.2% 0%
Nootropil®52.001.3%46.001.1% -11.54%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
United States1,69443.7%1,85144.3% +9.27%
Other Countries485.0012.5%319.007.6% -34.23%
Germany247.006.4%290.006.9% +17.41%
Japan207.005.3%268.006.4% +29.47%
Other196.005.1%292.007% +48.98%
Emerging Markets192.005%---
Italy154.004%154.003.7% 0%
Spain152.003.9%162.003.9% +6.58%
France150.003.9%161.003.9% +7.33%
Belgium35.000.9%33.000.8% -5.71%
Europe--328.007.9%-
Managers
NameAgeSinceTitle
Jean-Christophe Tellier-2011Chief Executive Officer & Executive Director
Evelyn du Monceau671984Chairman
Charl van Zyl, MBA502017Chief Operating Officer
Detlef Thielgen-2006Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich MD, PhD572006Chief Medical Officer & Executive Vice President
Ismail Kola, PhD602009Chief Scientific Officer, EVP & Head-New Medicines
Norman J. Ornstein-2008Independent Director
Albrecht de Graeve622010Independent Director
Charles-Antoine Janssen-2001Director
Jonkheer Cédric van Rijckevorsel, CFA-2014Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 194,505,658 114,788,778 59.0% 6,419,669 3.3% 59.0%
Shareholders
NameEquities%
Financière de Tubize SA 68,076,981 35.0%
Wellington Management Co. LLP 14,151,273 7.28%
Capital Research & Management Co. (World Investors) 11,051,809 5.68%
UCB SA 6,428,833 3.31%
Capital Research & Management Co. (Global Investors) 4,605,299 2.37%
The Vanguard Group, Inc. 2,967,750 1.53%
Schroder Investment Management Ltd. 2,476,102 1.27%
Schwarz Family 2,471,404 1.27%
BlackRock Fund Advisors 2,246,265 1.15%
Norges Bank Investment Management 1,994,994 1.03%
Holdings
NameEquities%Valuation
UCB (UCB) 6,428,8333.31%457,757,982 USD
Dermira Inc (DERM) 1,841,2344.43%49,713,318 USD
Arix Bioscience PLC (ARIX) 3,869,9024.03%10,410,075 USD
Wilex AG (WL6) 1,132,8087.57%3,943,962 USD
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Euronext 100, PEA
Stock Exchange Codes
- Bloomberg Code :  UCB:BB
- Reuters Code :  UCB.BR
- Datastream Code :  B:UCB
Company contact information
UCB
allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium

Phone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : http://www.ucb.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
UCB-0.44%14 016
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423
AMGEN25.17%135 858
SANOFI8.71%124 607
BAYER19.19%115 363
CELGENE CORPORATION17.89%108 637
BRISTOL-MYERS SQUIBB COMPANY11.72%105 250
GLAXOSMITHKLINE-2.94%98 264
NOVO NORDISK A/S16.92%96 545
ABBOTT LABORATORIES42.28%95 664
ELI LILLY AND COMPANY17.68%94 751
ASTRAZENECA15.54%86 638
ALLERGAN PLC-2.14%66 119
SHIRE-17.85%46 206
TAKEDA PHARMACEUTICAL CO LTD30.38%44 083
ASTELLAS PHARMA INC-7.07%27 260
JIANGSU HENGRUI MEDICINE CO LTD38.26%27 174
Connections : UCB
Biotechnology Innovation Organization
Flanders-China Chamber of Commerce
Hoechst Marion Roussel, Inc.
The Belgische Commissie Corporate Governance
FBNet Belgium
SCR-Sibelco NV
Pharmaceutical Research & Manufacturers of America
Alcatel Trade International AG
Johann Wolfgang Goethe-Universität Frankfurt am Main
U.S. Capitol Historical Society
The Conference Board, Inc.
Belgian Luxembourg Chamber of Commerce for Russia & Belarus
Université Libre de Bruxelles
European Federation of Pharmaceutical Industries & Assns
Telenet Group BVBA
Wallon Institute for Life Lead Sciences
Concours Reine Elisabeth
Astex Therapeutics Ltd.
International Business Leaders Advisory Council
Ucb Pharma OY Finland
IDS Capital (UK) Ltd.
The Campaign Legal Center
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem